At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 77 enrolled
Drug / intervention
Ipragliflozin +1 moredrug
Likely dose
Ipragliflozin 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Multicenter, Open-label Long-term Treatment Trial to Assess the Safety and Efficacy of Addition of Ipragliflozin in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin Monotherapy in Addition to Diet and Exercise Therapy
In Brief
A Phase 3 clinical trial evaluating Ipragliflozin and Sitagliptin for Type 2 Diabetes Mellitus. Completed, enrolled 77 participants.
Detailed Summary
This is a study to assess the safety and efficacy of the addition of ipragliflozin to sitagliptin in Japanese participants with Type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on sitagliptin, diet, and exercise therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 2015
Enrollment StartOct 2015
Primary CompletionMar 2017
TodayJul 2026
First PostedSep 30, 2015
Enrollment StartOct 26, 2015
Primary CompletionMar 7, 2017
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.8 years ago
Interventions
Ipragliflozindrug
one 50 mg tablet QD
Sitagliptindrug
one 50 mg tablet QD